anti-BCMA-CAR-transduced T cells

Anti-BCMA-CAR-transduced T cells are a form of cell therapy in which human T lymphocytes are genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets B-cell maturation antigen (BCMA), also known as TNF receptor superfamily 17. BCMA is highly expressed on the surface of malignant plasma cells in multiple myeloma. Upon infusion into the patient, these modified T cells recognize and bind to BCMA-expressing tumor cells, leading to their selective destruction through cytotoxic mechanisms and cytokine release. Anti-BCMA CAR-T cell therapy is primarily developed for relapsed or refractory multiple myeloma and has shown significant efficacy in this setting[2][3][4]. The approach can be autologous or allogeneic; ALLO-715 is an example of an allogeneic product[1]. The mechanism involves direct tumor cell killing as well as modulation of the tumor microenvironment via soluble factors released by activated CAR-Ts[2][6].

Other names

anti-BCMA CAR-T cellsBCMA-targeted CAR-T cellsB-cell maturation antigen chimeric antigen receptor T cells